Statins

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

Top

Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014. [ePub ahead of print] doi: 10.1016/S2213-8587(14)70173-1.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Top

Dormuth CR, Filion KB, Paterson JM, et al; for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.

Statins and the risk of diabetes: evidence from a large population-based cohort study

Top

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Top

Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. Sattar and colleagues conducted a meta-analysis to assess whether a relationship between statin use and development of diabetes exists.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

Effects of combination lipid therapy in type 2 diabetes mellitus

Top

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574. We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.

1 2 3 Next